Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis - Scorecard - MDSpire

Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis

  • By

  • Catherine G. Tran

  • Carine Dornbush

  • Braden S. Jensen

  • Sarah L. Mott

  • Elise E. H. Fannon

  • Austin C. Stark

  • Meghan E. Mali

  • Daniel J. Berg

  • Erin E. Talbert

  • Carlos H. F. Chan

  • February 5, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsObesity associated with metabolic and hormonal alterations, inflammation, and potential impact on survival outcomes.
Target Population
Care Setting

Key Highlights

  • highlight_3

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider weight loss and maintenance of normal weight in cancer survivors, referencing specific guidelines.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Most patients received multi-agent chemotherapy (e.g., FOLFOX, FOLFIRI); no significant differences in treatment received by BMI group.

        Clinical Best Practices

        • practice_2

        References

        Original Source(s)

        Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis

        • by Catherine G. Tran, Carine Dornbush, Braden S. Jensen, Sarah L. Mott, Elise E. H. Fannon, Austin C. Stark, Meghan E. Mali, Daniel J. Berg, Erin E. Talbert, Carlos H. F. Chan

        • February 5, 2026

        Related Content

        A Meta-Analysis on the Effectiveness and Safety of FOLFOX Plus Bevacizumab for Colorectal Cancer Treatment

        HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology

        Colorectal Cancer Treatment During Pregnancy

        Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.